$HCSG
HEALTHCARE SERVICES GROUP INC

2014 Q2 Form 10-Q Financial Statement

#000073101214000056 Filed on July 24, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2013 Q2
Revenue $319.3M $273.6M
YoY Change 16.7% 2.43%
Cost Of Revenue $275.8M $234.6M
YoY Change 17.57% 1.91%
Gross Profit $43.48M $39.00M
YoY Change 11.48% 5.69%
Gross Profit Margin 13.62% 14.25%
Selling, General & Admin $22.24M $19.36M
YoY Change 14.86% 4.53%
% of Gross Profit 51.15% 49.65%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.800M $1.300M
YoY Change 38.46% 0.0%
% of Gross Profit 4.14% 3.33%
Operating Expenses $22.24M $19.36M
YoY Change 14.86% 4.53%
Operating Profit $21.24M $19.64M
YoY Change 8.15% 6.86%
Interest Expense $800.0K $200.0K
YoY Change 300.0% -300.0%
% of Operating Profit 3.77% 1.02%
Other Income/Expense, Net
YoY Change
Pretax Income $22.04M $19.86M
YoY Change 11.0% 8.61%
Income Tax $8.122M $6.925M
% Of Pretax Income 36.85% 34.87%
Net Earnings $13.92M $12.93M
YoY Change 7.64% 14.25%
Net Earnings / Revenue 4.36% 4.73%
Basic Earnings Per Share $0.20 $0.19
Diluted Earnings Per Share $0.20 $0.19
COMMON SHARES
Basic Shares Outstanding 70.44M shares 68.60M shares
Diluted Shares Outstanding 71.21M shares 69.37M shares

Balance Sheet

Concept 2014 Q2 2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $68.40M $85.19M
YoY Change -19.71% 10.63%
Cash & Equivalents $57.27M $63.16M
Short-Term Investments $11.10M $22.03M
Other Short-Term Assets $13.60M $9.800M
YoY Change 38.78% -6.67%
Inventory $32.90M $28.60M
Prepaid Expenses $13.57M $9.767M
Receivables $205.2M $165.7M
Other Receivables $0.00 $0.00
Total Short-Term Assets $320.0M $289.3M
YoY Change 10.62% 15.57%
LONG-TERM ASSETS
Property, Plant & Equipment $11.48M $10.20M
YoY Change 12.56% 0.7%
Goodwill $44.44M $16.96M
YoY Change 162.09% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $38.00K $38.00K
YoY Change 0.0% 0.0%
Total Long-Term Assets $121.2M $66.11M
YoY Change 83.31% 6.46%
TOTAL ASSETS
Total Short-Term Assets $320.0M $289.3M
Total Long-Term Assets $121.2M $66.11M
Total Assets $441.2M $355.4M
YoY Change 24.14% 13.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $47.28M $31.24M
YoY Change 51.35% 49.75%
Accrued Expenses $43.20M $39.00M
YoY Change 10.77% 11.75%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $96.14M $75.27M
YoY Change 27.73% 26.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $43.20M $36.60M
YoY Change 18.03% 18.45%
Total Long-Term Liabilities $43.20M $36.60M
YoY Change 18.03% 18.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $96.14M $75.27M
Total Long-Term Liabilities $43.20M $36.60M
Total Liabilities $139.4M $111.9M
YoY Change 24.58% 23.78%
SHAREHOLDERS EQUITY
Retained Earnings $131.8M $132.0M
YoY Change -0.18% 5.58%
Common Stock $181.2M $122.9M
YoY Change 47.46% 9.21%
Preferred Stock
YoY Change
Treasury Stock (at cost) $11.13M $11.37M
YoY Change -2.13% -27.12%
Treasury Stock Shares 1.829M shares 1.899M shares
Shareholders Equity $301.8M $243.5M
YoY Change
Total Liabilities & Shareholders Equity $441.2M $355.4M
YoY Change 24.14% 13.76%

Cashflow Statement

Concept 2014 Q2 2013 Q2
OPERATING ACTIVITIES
Net Income $13.92M $12.93M
YoY Change 7.64% 14.25%
Depreciation, Depletion And Amortization $1.800M $1.300M
YoY Change 38.46% 0.0%
Cash From Operating Activities -$3.500M $19.00M
YoY Change -118.42% 5.56%
INVESTING ACTIVITIES
Capital Expenditures -$1.200M -$700.0K
YoY Change 71.43% -30.0%
Acquisitions
YoY Change
Other Investing Activities $700.0K $200.0K
YoY Change 250.0% -166.67%
Cash From Investing Activities -$500.0K -$500.0K
YoY Change 0.0% -61.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.50M -10.10M
YoY Change 3.96% 8.6%
NET CHANGE
Cash From Operating Activities -3.500M 19.00M
Cash From Investing Activities -500.0K -500.0K
Cash From Financing Activities -10.50M -10.10M
Net Change In Cash -14.50M 8.400M
YoY Change -272.62% 13.51%
FREE CASH FLOW
Cash From Operating Activities -$3.500M $19.00M
Capital Expenditures -$1.200M -$700.0K
Free Cash Flow -$2.300M $19.70M
YoY Change -111.68% 3.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
835000 shares
us-gaap Interest Paid
InterestPaid
0 USD
CY2014Q2 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
205172000 USD
CY2013Q4 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
189107000 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
43682000 USD
CY2014Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
47278000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.019
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.015
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
535000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.24
us-gaap Stock Issued During Period Value Dividend Reinvestment Plan
StockIssuedDuringPeriodValueDividendReinvestmentPlan
28000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.81
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
518000 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1851000 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1842000 USD
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3834000 USD
CY2014Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
5381000 USD
CY2013Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1878000 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
20699000 USD
CY2014Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
22299000 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
49000 USD
CY2014Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
56000 USD
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
168329000 USD
CY2014Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
180441000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1350000 USD
us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
885000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1531000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1196000 USD
CY2014Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
4794000 USD
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3919000 USD
CY2014Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
857000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1084000 USD
CY2013Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
542000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1685000 USD
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
578000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
548000 shares
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
552000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
785000 shares
CY2014Q2 us-gaap Assets
Assets
441217000 USD
CY2013Q4 us-gaap Assets
Assets
425342000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
309192000 USD
CY2014Q2 us-gaap Assets Current
AssetsCurrent
320030000 USD
CY2014Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
92000 USD
CY2013Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
83000 USD
CY2013Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000 USD
CY2014Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 USD
CY2013Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
11364000 USD
CY2014Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
11012000 USD
CY2014Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
3296000 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1846000 USD
CY2014Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
11104000 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
11445000 USD
us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
4000 USD
hcsg Increase Decrease In Deferred Compensation Funding
IncreaseDecreaseInDeferredCompensationFunding
1926000 USD
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57269000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64155000 USD
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63160000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68949000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5789000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6886000 USD
CY2014Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4963000 shares
CY2014Q2 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.17250
CY2014Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.17125
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72138000 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71868000 shares
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72138000 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71868000 shares
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
719000 USD
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
721000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
28567000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
27804000 USD
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
12827000 USD
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
13927000 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments, as defined by U.S. GAAP, which potentially subject us to concentrations of credit risk, consist principally of cash and cash equivalents, marketable securities, deferred compensation funding and accounts and notes receivable. We define our marketable securities as fixed income investments which are highly liquid investments that can be readily purchased or sold using established markets. At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, substantially all of our cash and cash equivalents, and marketable securities were held in one large financial institution located in the United States.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our clients are concentrated in the health care industry, primarily providers of long-term care. Many of our clients&#8217; revenues are highly contingent on Medicare, Medicaid and third party payors&#8217; reimbursement funding rates. Congress has enacted a number of major laws during the past decade that have significantly altered, or threatened to alter, overall government reimbursement for nursing home services. These changes and lack of substantive reimbursement funding rate reform legislation, as well as other trends in the long-term care industry have affected and could adversely affect the liquidity of our clients, resulting in their inability to make payments to us on agreed upon payment terms. These factors, in addition to delays in payments from clients, could result in significant additional bad debts in the future.</font></div></div>
us-gaap Cost Of Services
CostOfServices
543186000 USD
CY2014Q2 us-gaap Cost Of Services
CostOfServices
275815000 USD
us-gaap Cost Of Services
CostOfServices
469793000 USD
CY2013Q2 us-gaap Cost Of Services
CostOfServices
234602000 USD
us-gaap Debt Instrument Term
DebtInstrumentTerm
P5Y
CY2014Q2 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
24387000 USD
CY2013Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
22771000 USD
CY2014Q2 us-gaap Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
24003000 USD
CY2013Q4 us-gaap Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
22200000 USD
CY2014Q2 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
0 USD
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
2339000 USD
CY2013Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
13274000 USD
CY2014Q2 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
14376000 USD
CY2013Q4 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
0 USD
CY2014Q2 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
254000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2707000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3581000 USD
CY2014Q2 us-gaap Dividend Payable Date To Be Paid Day Month And Year
DividendPayableDateToBePaidDayMonthAndYear
2014-06-27
CY2014Q1 us-gaap Dividend Payable Date To Be Paid Day Month And Year
DividendPayableDateToBePaidDayMonthAndYear
2014-03-28
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
24263000 USD
CY2014Q1 us-gaap Dividends Payable Date Of Record Day Month And Year
DividendsPayableDateOfRecordDayMonthAndYear
2014-02-21
CY2014Q2 us-gaap Dividends Payable Date Of Record Day Month And Year
DividendsPayableDateOfRecordDayMonthAndYear
2014-05-23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
CY2013Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.20
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.40
CY2013Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.19
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.29
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.28
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.37
CY2014Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
32543000 USD
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
37162000 USD
CY2013Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
5982000 USD
CY2014Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
7847000 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
1128000 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
885000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
12909000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
14594000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
7525000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
3241000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1638000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
2130000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2328000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2427000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2698000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
36581000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
36281000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
21987000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
23372000 USD
CY2014Q2 us-gaap Goodwill
Goodwill
44438000 USD
CY2013Q4 us-gaap Goodwill
Goodwill
40183000 USD
us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
4255000 USD
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0 USD
CY2013 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0 USD
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
22043000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
45172000 USD
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
19858000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
38815000 USD
CY2014Q2 us-gaap Income Loss From Extraordinary Items Net Of Tax Per Basic Share
IncomeLossFromExtraordinaryItemsNetOfTaxPerBasicShare
0.00
CY2013Q2 us-gaap Income Loss From Extraordinary Items Net Of Tax Per Basic Share
IncomeLossFromExtraordinaryItemsNetOfTaxPerBasicShare
0.00
us-gaap Income Loss From Extraordinary Items Net Of Tax Per Basic Share
IncomeLossFromExtraordinaryItemsNetOfTaxPerBasicShare
-0.01
us-gaap Income Loss From Extraordinary Items Net Of Tax Per Basic Share
IncomeLossFromExtraordinaryItemsNetOfTaxPerBasicShare
-0.01
us-gaap Interest Paid
InterestPaid
73000 USD
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6925000 USD
CY2014Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8122000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10928000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16612000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
10737000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
8531000 USD
us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
26812000 USD
us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
16695000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
2573000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
3503000 USD
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
2922000 USD
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
3031000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-27000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
472000 USD
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1942000 USD
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
8454000 USD
us-gaap Increase Decrease In Other Employee Related Liabilities
IncreaseDecreaseInOtherEmployeeRelatedLiabilities
-1989000 USD
us-gaap Increase Decrease In Other Employee Related Liabilities
IncreaseDecreaseInOtherEmployeeRelatedLiabilities
-3338000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1085000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4191000 USD
us-gaap Increase Decrease In Workers Compensation Liabilities
IncreaseDecreaseInWorkersCompensationLiabilities
740000 USD
us-gaap Increase Decrease In Workers Compensation Liabilities
IncreaseDecreaseInWorkersCompensationLiabilities
1137000 USD
CY2014Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
766000 shares
CY2013Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
771000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
759000 shares
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
174000 USD
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
303000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1184000 USD
CY2013Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
219000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1253000 USD
CY2014Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
803000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
425342000 USD
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
441217000 USD
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
96140000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
99103000 USD
CY2014Q2 us-gaap Line Of Credit
LineOfCredit
0 USD
us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2018-12-18
CY2014Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
125000000 USD
CY2013Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2516000 USD
CY2014Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2524000 USD
CY2013Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
11445000 USD
CY2014Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
11104000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-17070000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-19516000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2197000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2699000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
13980000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
14827000 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
12933000 USD
us-gaap Net Income Loss
NetIncomeLoss
27887000 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
13921000 USD
us-gaap Net Income Loss
NetIncomeLoss
28560000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3450000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2115000 USD
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
13921000 USD
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
12933000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
28560000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
27887000 USD
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
13921000 USD
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
12933000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
28560000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
27887000 USD
CY2013Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
5779000 USD
CY2014Q2 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
4861000 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2014Q2 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
48 state
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8528000 USD
CY2014Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2609000 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
38000 USD
CY2014Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
38000 USD
us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
10000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-83000 USD
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7000 USD
CY2013Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-106000 USD
CY2014Q2 us-gaap Other Inventory
OtherInventory
32919000 USD
CY2013Q4 us-gaap Other Inventory
OtherInventory
32447000 USD
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
24263000 USD
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
22931000 USD
CY2014Q2 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
12186000 USD
CY2014Q1 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
12077000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
4597000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1937000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1702000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2738000 USD
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9699000 USD
CY2014Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
13566000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
53000 USD
CY2014Q2 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
1004000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
1875000 USD
CY2013Q2 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
3000000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
3000000 USD
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
363000 USD
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
150000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4680000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3834000 USD
CY2014Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33783000 USD
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
32003000 USD
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11484000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11304000 USD
CY2014Q2 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
258000 USD
CY2013Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
305000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
650000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1550000 USD
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
4000 USD
CY2014Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
3000 USD
CY2013Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
16000 USD
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
16000 USD
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
3000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
127464000 USD
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
131761000 USD
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
631460000 USD
CY2014Q2 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
319295000 USD
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
547508000 USD
CY2013Q2 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
273604000 USD
hcsg Unrealized Gain Loss On Securities Related To Deferred Compensation Fund
UnrealizedGainLossOnSecuritiesRelatedToDeferredCompensationFund
759000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2280000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
65000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
21.47
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
535000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.369
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
44286000 USD
CY2014Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22240000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
40153000 USD
CY2013Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
19363000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1531000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1196000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.024
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.028
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.389
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2683000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2483000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.05
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.48
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
14.35
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
28.02
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1521000 shares
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1561000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
64000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
5.98
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
6.27
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.78
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
511000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.38
hcsg Line Of Credit Facility Number Of Financial Covenants
LineOfCreditFacilityNumberOfFinancialCovenants
1 financial_covenant
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
270000 shares
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2013Q4 hcsg Housekeeping Equipment And Office Furniture Gross
HousekeepingEquipmentAndOfficeFurnitureGross
29182000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
285143000 USD
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
301847000 USD
CY2013Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
1892000 shares
CY2014Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
1829000 shares
CY2013Q4 us-gaap Treasury Stock Value
TreasuryStockValue
11418000 USD
CY2014Q2 us-gaap Treasury Stock Value
TreasuryStockValue
11132000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates in Financial Statements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In preparing financial statements in conformity with U.S. GAAP, we make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates are used for, but not limited to, our allowance for doubtful accounts, accrued insurance claims, asset valuations and review for potential impairment, and deferred taxes. The estimates are based upon various factors including current and historical trends, as well as other pertinent industry and regulatory authority information. We regularly evaluate this information to determine if it is necessary to update the basis for our estimates and to compensate for known changes.</font></div></div>
CY2014Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71206000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71140000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69366000 shares
CY2013Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69370000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70381000 shares
CY2014Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70440000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68531000 shares
CY2013Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68599000 shares
CY2013Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
7853000 USD
CY2014Q2 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
8075000 USD
CY2014Q2 us-gaap Workers Compensation Liability Noncurrent
WorkersCompensationLiabilityNoncurrent
18843000 USD
CY2013Q4 us-gaap Workers Compensation Liability Noncurrent
WorkersCompensationLiabilityNoncurrent
18325000 USD
hcsg Adjustmentto Paidin Capital Purchase Price Allocation Adjustment
AdjustmenttoPaidinCapitalPurchasePriceAllocationAdjustment
3934000 USD
CY2014Q2 hcsg Available For Sale Securities Debt Maturities After One Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue
6065000 USD
CY2013Q4 hcsg Available For Sale Securities Debt Maturities After One Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue
7113000 USD
CY2014Q2 hcsg Available For Sale Securities Debt Maturities After Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterThreeYearsFairValue
1743000 USD
CY2013Q4 hcsg Available For Sale Securities Debt Maturities After Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterThreeYearsFairValue
2486000 USD
hcsg Common Stock Weighted Average Dividends Per Share Cash Paid
CommonStockWeightedAverageDividendsPerShareCashPaid
0.33
hcsg Common Stock Weighted Average Dividends Per Share Cash Paid
CommonStockWeightedAverageDividendsPerShareCashPaid
0.34
CY2013Q2 hcsg Common Stock Weighted Average Dividends Per Share Cash Paid
CommonStockWeightedAverageDividendsPerShareCashPaid
0.17
CY2014Q2 hcsg Common Stock Weighted Average Dividends Per Share Cash Paid
CommonStockWeightedAverageDividendsPerShareCashPaid
0.17
hcsg Deferred Income Tax Expense Benefit Excluding Tax Benefit From Equity Compensation Plans
DeferredIncomeTaxExpenseBenefitExcludingTaxBenefitFromEquityCompensationPlans
1486000 USD
hcsg Deferred Income Tax Expense Benefit Excluding Tax Benefit From Equity Compensation Plans
DeferredIncomeTaxExpenseBenefitExcludingTaxBenefitFromEquityCompensationPlans
-1305000 USD
hcsg Description For Terms Of Service Agreement
DescriptionForTermsOfServiceAgreement
Our agreements with clients typically provide for a one year service term, cancelable by either party upon 30 to 90 days’ notice after the initial 90-day period.
CY2014Q2 hcsg Housekeeping Equipment And Office Furniture Gross
HousekeepingEquipmentAndOfficeFurnitureGross
31001000 USD
hcsg Increase Decrease In Deferred Compensation Funding
IncreaseDecreaseInDeferredCompensationFunding
1803000 USD
hcsg Share Based Compensation Arrangement By Share Based Payment Award Maximum Term Of Grants
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumTermOfGrants
P10Y
CY2013Q2 hcsg Share Based Compensation Arrangement By Share Based Payment Award Options Grants Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsGrantDateFairValue
3412000 USD
CY2014Q2 hcsg Share Based Compensation Arrangement By Share Based Payment Award Options Grants Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsGrantDateFairValue
4268000 USD
CY2014Q2 hcsg Share Based Compensation Shares Authorized Under Stock Option Plan Exercise Price Range Exercisable Options Weighted Average Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlanExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice
27.56
hcsg Share Based Compensation Shares Authorized Under Stock Option Plan Exercise Price Range Exercisable Options Weighted Average Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlanExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice
26.49
CY2013Q2 hcsg Share Based Compensation Shares Authorized Under Stock Option Plan Exercise Price Range Exercisable Options Weighted Average Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlanExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice
23.50
hcsg Share Based Compensation Shares Authorized Under Stock Option Plan Exercise Price Range Exercisable Options Weighted Average Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlanExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice
23.50
hcsg Unrealized Gain Loss On Securities Related To Deferred Compensation Fund
UnrealizedGainLossOnSecuritiesRelatedToDeferredCompensationFund
888000 USD
hcsg Lineof Credit Facility Increase Decrease Remaining Borrowing Capacity
LineofCreditFacilityIncreaseDecreaseRemainingBorrowingCapacity
-51520000 USD
CY2014Q2 hcsg Number Of Subsidiaries
NumberOfSubsidiaries
3 subsidiary
CY2011Q3 hcsg Percentage Of Reduction To Medicare Payments To Nursing Centers
PercentageOfReductionToMedicarePaymentsToNursingCenters
0.111
hcsg Percentage Of Revenue And Income Earned In One Geographic Segment
PercentageOfRevenueAndIncomeEarnedInOneGeographicSegment
0.99
hcsg Period Of Amortization Of Inventories And Supplies
PeriodOfAmortizationOfInventoriesAndSupplies
P24M
hcsg Service Agreements Duration Of Service
ServiceAgreementsDurationOfService
P1Y
hcsg Service Agreements Initial Period
ServiceAgreementsInitialPeriod
P90D
hcsg Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodTotalFairValue
2051000 USD
hcsg Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodTotalFairValue
1897000 USD
dei Document Period End Date
DocumentPeriodEndDate
2014-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000731012
CY2014Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
70330000 shares
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
HEALTHCARE SERVICES GROUP INC

Files In Submission

Name View Source Status
0000731012-14-000056-index-headers.html Edgar Link pending
0000731012-14-000056-index.html Edgar Link pending
0000731012-14-000056.txt Edgar Link pending
0000731012-14-000056-xbrl.zip Edgar Link pending
ceosection302certification.htm Edgar Link pending
cfosection302certification.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hcsg-20140630.xml Edgar Link completed
hcsg-20140630.xsd Edgar Link pending
hcsg-20140630_cal.xml Edgar Link unprocessable
hcsg-20140630_def.xml Edgar Link unprocessable
hcsg-20140630_lab.xml Edgar Link unprocessable
hcsg-20140630_pre.xml Edgar Link unprocessable
hcsg10qq22014.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
section906certificationq22.htm Edgar Link pending
Show.js Edgar Link pending